GlassScriptPhysician profile
Thomas F Okrasinski
NPI 1700252095
$2,171.14
in general payments reported to CMS, 2019-2025
27 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $489 · 2023: $415 · 2024: $531 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355 · Education: $19.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.28 |
| Education | $19.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $322.59 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $306.75 | 2021-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $185.04 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $175.74 | 2021-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $159.07 | 2022-2023 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $157.13 | 2022-2025 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $145.87 | 2021-2025 | Ultomiris |
| Horizon Therapeutics Plc | $136.83 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.89 | 2024-2025 | |
| Akebia Therapeutics INC | $73.14 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $41.54 | 2022-2025 | Tarpeyo |
| Xeris Pharmaceuticals, INC. | $38.53 | 2023 | Keveyis |
| Vifor Pharma, INC. | $34.72 | 2024 | Veltassa |
| Ardelyx, INC. | $34.48 | 2024-2025 | Ibsrela |
| Amgen INC. | $29.36 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $27.74 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.57 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $22.97 | 2022 | |
| Recor Medical INC | $21.94 | 2024 | Paradise Renal Denervation System |
| Novo Nordisk INC | $21.04 | 2025 | |
| Amag Pharmaceuticals, INC. | $20.45 | 2021 | |
| Opko Pharmaceuticals, LLC | $19.86 | 2023 | Rayaldee |
| Kyowa Kirin, INC. | $19.65 | 2024 | Crysvita |
| Medtronic, INC. | $17.07 | 2023 | Onyx Frontier |
| Daiichi Sankyo INC. | $16.81 | 2022 | |
| Biomerieux INC | $14.86 | 2023 | |
| Arbor Pharmaceuticals, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Okrasinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.